Society Logo
ME/CFS Australia Ltd
Please click here to donate ME/CFS Australia (SA) Inc
 
 
Facebook
 
ME/CFS AUSTRALIA (SA) INC

Registered Charity 698

Email:
sacfs@sacfs.asn.au

Mailing address:
PO Box 28,
Hindmarsh,
South Australia 5007

Office:
Suite 506,
North Terrace House,
19 North Terrace,
Hackney, SA, 5069


Phone:
1300 128 339

Office Hours:
Wednesdays, 11am-3pm

ME/CFS Australia (SA) Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.

Disclaimer

ME/CFS Australia (SA) Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.

Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.

Become a Member
PDF Application Form (PDF, 277KB)
Why become a member?

Two Fibromyalgia medications don't stand out when compared to placebo

Saturday 13 April 2013

 

From About.com's Carol Eustice:

 

Fibromyalgia tender pointsTwo Fibromyalgia Medications Don't Stand Out When Compared to Placebo

By Carol Eustice, About.com Guide
February 21, 2013

Fibromyalgia affects more than 5 million Americans, primarily women. According to a review published in The Cochrane Library, two medications commonly prescribed to relieve fibromyalgia pain help some patients, but cause problems for others. Cymbalta (duloxetine) and Savella (milnacipran) had a small incremental effect over placebo in reducing pain. The number of patients who had to stop the drugs due to adverse events was higher for Cymbalta and Savella than for placebo. The drugs were not much better than placebo in reducing fatigue and limitations of quality of life.

Ten studies involving more than 6,000 fibromyalgia patients who were given Cymbalta, Savella, or placebo for up to 6 months were reviewed. Researchers concluded that the drugs should not be prescribed alone for fibromyalgia. An approach that would utilize medications in patients who find them helpful, exercise to improve mobility, and counseling to improve coping skills was recommended in place of medication alone. Later this year, The Cochrane Library is expected to publish a review of Lyrica (pregabalin), the other medication approved for fibromyalgia in the U.S.

Related Articles:

Follow Me:

Facebook | Twitter | Message Board | Newsletter

Image A.D.A.M.

 

The above, with comments, originally appeared here.

 


Arrow right

More Fibromyalgia News

 


 

blog comments powered by Disqus
Previous Previous Page